AZ-AXWAY
30.11.2022 08:01:52 CET | Business Wire | Press release
Axway (Euronext: AXW.PA), a leading provider of API management and integration software, today announced new data from its inaugural 2022 Open Everything Strategy Survey Report. Polling nearly 1,000 IT leaders, architects, and developers about their digital strategies and top concerns, the survey found nearly 40% of organizations are in the process of adopting a new hybrid approach for their IT infrastructure. The transformation comes as 68% of respondents cite their fears about API sprawl.
The survey data reflects responses from those engaged primarily in API development (893) and managed file transfer (MFT) services (102). Ensuring data security and controlling API sprawl were top concerns, with over two-thirds (68%) worrying about complexity due to sprawl and almost half (48%) of respondents ranking “increased security challenges” as their single greatest concern with API growth. Respondents again cited security as far and away the most important criteria when creating an API (30% among API respondents) and when setting up a new MFT service (48% among MFT respondents).
“Enterprises are in the thick of digital transformation and accompanying cloud and data migrations have made it possible to free up data so it can be exchanged, reused and remixed to fuel innovation and business growth. But that’s messy,” said Vince Padua, Chief Innovation and Technology Officer at Axway. “It brings complexity and security challenges that must be answered by using truly universal API management—that bridges the gap between API development and consumption and opens everything, lines of business and innovation, while building on and out from heritage infrastructure.”
The survey results indicate that budgets for API management have increased over the past two years and that security is top of mind as companies begin to unlock the full value of their data to create new digital experiences, markets and opportunities for revenue. Half of those surveyed reported modestly elevated API management budgets, with about 34% of respondents seeing increases up to 25%. Less than 20% of respondents saw budget decreases.
Drilling down further into security strategy and the impending skills gap
Digging deeper, the survey found that a significant majority, 59%, employ user authentication as a top strategy to secure APIs, and almost two-thirds of the API respondents (61%) said data encryption can help them personally feel their data is more secure. They also cited developing a more holistic approach to security as the number one strategy for protecting personal data.
When a member logs into our online channels or walks into one of our branches, we want to personalize their experience in real time. To achieve this, we targeted a high-performance API integration layer,” said Ravi Peru, Chief Information Officer at Community America Credit Union.
"When you have more than 50 products, handling integration in an agile way is very important," added Peru. "With Axway, we can interface with anything and move data between any internal systems we want. That would be really slow with point-to-point integration, but Axway makes it quick and easy."
Security factors into cloud strategy as well. Among the most significant challenges inhibiting cloud strategy, according to respondents, are:
- 53% – Dealing with different security requirements for regional instances of cloud infra
- 55% – Tracking and controlling the flow of personal data into and through the cloud
One of the most alarming, but not entirely surprising data points, deals with concerns about talent: 86% of API respondents fear an expertise gap in the coming years, where companies will not have the skilled software and IT infrastructure talent they need to innovate.
Click here to see the full report.
Survey Methodology
The 2022 Open Everything Strategy Survey was conducted between July 21 and August 16 of 2022 among two similar, but divided subsets of respondents: API development and MFT integration professionals. Axway engaged in direct email outreach among its contacts with opt-in email addresses, and received nearly 1,000 responses, including 893 from those in API development and 102 in MFT services, from various locations throughout the world.
About Axway
Axway enables enterprises to securely open everything by integrating and moving data across a complex world of new and old technologies. Axway’s API-driven B2B integration and MFT software, refined over 20 years, complements Axway Amplify, an open API management platform that makes APIs easier to discover and reuse across multiple teams, vendors, and cloud environments. Axway has helped over 11,000 businesses unlock the full value of their existing digital ecosystems to create brilliant experiences, innovate new services, and reach new markets. Learn more at axway.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129006117/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom